
On December 2, 2022, the Russian Ministry of Health registered Pembroria, a pembrolizumab biosimilar made by BIOCAD. [1] Merck’s own 10-K says the US compound patent family for Keytruda expires in 2028. [2] The gap between those two dates is about six years. This article tests what that gap means, and where it does not mean what it seems to mean.
BIOCAD is a Russian biotechnology company that sells biosimilars of Roche and Merck oncology drugs and a daratumumab product. It also runs its own patent fights, export registrations and original-drug programs. Western competitive intelligence teams rarely track it. This article assembles the public record from Russian regulatory reports, Russian and US court records, an SEC filing, and trade press. It adds calculations that no single source gives.
The Short Answer: Five Findings on BIOCAD’s Oncology Patent Position
BIOCAD has registered a pembrolizumab biosimilar in Russia and Vietnam. It has lost one patent challenge against Roche and faces one infringement suit from Genentech. It works in a legal system that lets the government license patents with no compensation to holders from 48 countries. Here are the five findings, each stated so you can quote it.
- Finding 1: BIOCAD’s pembrolizumab biosimilar Pembroria was registered in Russia 148 days after the filing was reported, and about 6.1 years before the 2028 US patent expiry that Merck discloses. (Calculated from [3], [1] and [2].)
- Finding 2: Three pembrolizumab analogues are now registered in Russia: BIOCAD’s Pembroria, R-Pharm’s Arfleyda and MIT’s Pembronext, which CinnaGen of Iran manufactures. [4]
- Finding 3: In February 2026, Rospatent rejected BIOCAD’s challenge to Russian patent 2426554, a Genentech pertuzumab formulation patent that runs to March 22, 2028. [5] Genentech then sued BIOCAD in the Moscow Arbitration Court. [6]
- Finding 4: Russian Government Decree 299 of March 6, 2022 sets compensation at 0% when Russia licenses a patent without consent from a holder in a designated country. [7] A May 2026 court ruling on semaglutide set a 1.75% royalty instead. [8]
- Finding 5: The 2025 Keytruda franchise made $31,680 million, which is 48.7% of Merck’s $65,011 million total sales. [2] The 48.7% is a calculation made for this article.
Methodology: What This Article Analyzed and How
Which Sources and Time Period Does This Analysis Use?
The analysis covers public records dated from 2016 to October 20, 2026. It uses one SEC filing (Merck’s FY2025 10-K), one US appellate opinion, Russian regulatory news from GxP News and Pharmvestnik, patent-law trade reports from Pearce IP and The Pharma Letter, one peer-reviewed trial paper, and clinical trial registry pages. Where a source reports another source’s information, this article says so.
How Were Records Selected and Calculated?
I included an event when a dated source reported it: a registration, a court filing, a court ruling, a patent expiry, or a licensed launch date. I counted each event once. If two sources gave different dates for one event, I used the source closest to the event and noted the conflict. Day counts and year gaps are my own arithmetic from those dates. This article labels each such figure as calculated.
What Are the Limits of This Data?
Four limits apply. First, I did not find Russian patent numbers for pembrolizumab, so I cannot map BIOCAD’s pembrolizumab product against specific Russian claims. Second, several Russian-language regulatory items reached me through trade press, not the State Register of Medicines. Third, BIOCAD’s statements about its own drugs are company claims. Fourth, I did not search the sanctions lists directly. Readers who need a legal answer must screen the lists themselves.
Definitions Used in This Article
A biosimilar is a biologic product that regulators judge highly similar to an approved reference product. Under US law, the FDA cannot approve a biosimilar application until 12 years after first licensure of the reference product. [9] Accelerated registration is a Russian procedure for drugs on a government list built to prevent shortages. Compulsory licensing means a government permits use of a patent without the holder’s consent. Loss of exclusivity (LOE) means the date when competition can legally start.
Who Is BIOCAD? Company Facts from Public Sources
How Big Is BIOCAD, and When Did It Start?
BIOCAD was founded about 20 years before 2022 by Dmitry Morozov as a pharmaceutical startup outside Moscow. [10] By 2021 it held more than 200 marketing authorizations in 30 countries and had more than 40 products in development. [10] It operated seven production and R&D sites certified to GMP, GLP and GCP standards. [10] The Torreya ranking of November 2021 placed it 16th among the world’s top biosimilar producers by value. It was the only Russian company on that list. [10]
The financial record is older. In 2018, BIOCAD reported net revenue of 21.7 billion rubles, up 39.5% on the year, and exports of 9.44% of revenue. [11] CEO Morozov told the Russian Investment Forum in Sochi that the company targeted 50% export revenue by 2023. [11] I found no audited recent revenue figure in the sources used, so this article does not estimate one.
What Platforms Does BIOCAD Use to Make Drugs?
BIOCAD runs three in-house platforms. MabNext covers monoclonal antibodies. ChemNext covers small molecules. GeneNext covers rAAV-based gene therapy. [10] The company’s MeganLiB phage library holds antibody genes from more than 1,000 healthy donors and about 10^11 independent clones. [10] Three marketed biosimilars (rituximab, bevacizumab and trastuzumab) ship to more than 20 countries. [10]
Is BIOCAD Sanctioned by the US, UK or EU?
The short answer: none of the sources I reviewed reports a sanctions designation of BIOCAD, but I did not search the lists myself. Screen the OFAC SDN list, the UK list and the EU list before any transaction.
The general rules help only a little. OFAC states that “humanitarian trade is not the target of U.S. sanctions,” and it points to General License 6D for certain medicine and medical-device activity. [12] A trade-compliance review reaches a similar view: sanctions do not directly target Russia’s pharmaceutical sector, and exceptions for medical supplies exist. [13] The same review says sanctions still hurt Russian medical supply through payment, shipping and ingredient problems. [13] That second point matters for BIOCAD’s strategy, because import substitution gains value when imports get harder.
Pembrolizumab: Keytruda’s Patent Clock Against BIOCAD’s Pembroria
When Does the Keytruda Patent Expire in Each Major Market?
Merck’s FY2025 10-K lists the Keytruda patent expiry as 2028 in the United States, 2028 in China, 2031 in France, Germany, Italy and Spain, and 2032 to 2033 in Japan. [2] The filing adds that the US compound patent family “contains two additional patents that expire in 2029 due to patent term adjustment,” and that Merck “expects that they will be the subject of litigation in the future.” [2] For Keytruda Qlex, the subcutaneous fixed combination with berahyaluronidase alfa, the 10-K lists US expiry in 2043 and EU expiry in 2031. [2]
| Jurisdiction | Keytruda (pembrolizumab) expiry | Keytruda Qlex expiry | Source |
|---|---|---|---|
| United States | 2028 (two further patents to 2029 via patent term adjustment) | 2043 | [2] |
| China | 2028 | N/A | [2] |
| EU (FR, DE, IT, ES) | 2031 | 2031 | [2] |
| Japan | 2032 to 2033 | N/A | [2] |
| Russia | Not reported in the sources reviewed | Not reported | None |
Why Do Sources Disagree on the US Expiry Month?
Merck gives the year only. A DrugPatentWatch pembrolizumab page describes US patent 8,354,509 as the central composition patent and gives a May 2028 expiry. [14] Targeted Oncology, reporting the Formycon and Zydus filing, gives December 2028. [15] The two dates differ by about seven months. I could not reconcile them from the sources I read. For planning, use 2028 as the year and treat the month as unsettled. A pediatric exclusivity extension could move a date again. [14]
Does the 12-Year Biologic Exclusivity Still Protect Keytruda in the US?
No. The FDA approved Keytruda on September 4, 2014, under BLA 125514. [14] The Biologics Price Competition and Innovation Act bars approval of a biosimilar until 12 years after first licensure. [9] Twelve years from September 4, 2014 is September 4, 2026. That date passed 46 days before the date of this article. This calculation is mine. It means patents, not regulatory exclusivity, now control US entry.
How Did BIOCAD Move From Trial to Registration for Pembrolizumab?
The record gives five dated steps.
| Date | Event | Source |
|---|---|---|
| Sept. 4, 2014 | FDA approves Keytruda (BLA 125514) | [14] |
| Nov. 2016 | Keytruda registered in Russia | [3] |
| Apr. 5, 2022 | Government Decree 593 builds the accelerated-registration list that includes pembrolizumab | [1] |
| July 5, 2022 | Russian Ministry of Health authorization for BIOCAD’s BCD-201-2 trial (Belarus authorization Sept. 28, 2022) | [16] |
| July 7, 2022 | Pharmvestnik reports BIOCAD’s registration filing for Pembroria | [3] |
| Dec. 2, 2022 | Ministry of Health registers Pembroria | [1] |
| 2023 onward | BIOCAD says it supplies anticancer drugs, including pembrolizumab, to Cuba free of charge | [17] |
| Oct. 31, 2025 | BIOCAD announces Cuban real-world data in metastatic, inoperable melanoma | [17] |
| Nov. 11, 2025 | Vietnam Ministry of Health grants a three-year marketing authorization | [17] |
From the Pharmvestnik filing report to registration is 148 days (calculated). From the FDA approval of Keytruda to Pembroria’s Russian registration is 8.2 years (calculated). From Keytruda’s Russian registration in November 2016 to Pembroria is 6.1 years (calculated, using November 1 as the working date).
What Does the Vietnam Approval Actually Show?
Vietnam approved Pembroria for three years. [17] Tuoi Tre reports that a UAE-based firm registered the product, that regulators will review immunogenicity, efficacy and risk management every three months, and that a representative called these requirements “higher than usual.” [18] Tuoi Tre also reports that the latest phase 3 study finished in January 2024. [18] The same article says Pembroria was approved in Russia in April 2022. That date conflicts with GxP News, which reports registration on December 2, 2022, and with BIOCAD’s own trial page, which shows trial authorization in July 2022. [1][16] This article uses the December 2022 date.
What Did the Cuba Data Report?
BIOCAD announced on October 31, 2025 that BCD-201 showed a favorable safety and efficacy profile in real-world use in Cuba, in patients with metastatic, inoperable melanoma. [17] This is a company announcement. It is not a controlled comparison, and I found no published dataset.
Who Else Is Building a Pembrolizumab Biosimilar?
Pearce IP lists Samsung Bioepis, Amgen, mAbxience, Sandoz, Celltrion, Bio-Thera and BioNTech as developers with clinical trials, and it notes an Alvotech and Dr. Reddy’s co-development deal. [17] Formycon’s FYB206 has licensing deals with MS Pharma for the Middle East and North Africa and with Zydus Lifesciences for the US and Canada. [19] Biocon planned to unveil a pembrolizumab biosimilar at the 2026 J.P. Morgan Healthcare Conference. [19]
What Is the First Public FDA Filing Status for a Pembrolizumab Biosimilar?
The FDA accepted Formycon and Zydus’s biologics license application for FYB206, according to a news release dated October 13, 2026. Targeted Oncology calls it the first publicly announced acceptance of a pembrolizumab biosimilar filing. [15] The companies submitted in Q3 2026. Under BsUFA, a decision could come in Q3 2027. [15] A Health Canada dossier is also filed. [15] The companies state that regulators have not yet established biosimilarity. [15]
The calendar gap is concrete. Pembroria had a Russian registration on December 2, 2022. FYB206’s FDA filing was accepted on October 13, 2026. That is 3.9 years (calculated). The FDA decision, if it follows the stated goal, would land in the year before the 2028 US patent expiry.
What Is at Stake: Keytruda Revenue and Russian Procurement Exposure
How Much Revenue Does the Keytruda Franchise Generate?
Keytruda and Keytruda Qlex made $31,680 million in worldwide sales in 2025. That is about 48.7% of Merck’s total 2025 sales of $65,011 million. The percentage is a calculation made for this article. Merck’s filing does not state it. [2]
Keytruda and Keytruda Qlex worldwide sales: $31,680 million in 2025, against total Merck sales of $65,011 million. (Merck & Co., Inc., Form 10-K for fiscal year 2025) [2]
This concentration explains why the 2028 US date matters to Merck, and why Merck’s filing says it expects litigation over the two 2029 patents. [2] It does not explain BIOCAD’s commercial pull. BIOCAD sells in Russia and in export markets, not in the US.
How Large Is the Russian Pembrolizumab Market?
Pembrolizumab ranked first in Russian state procurement of anticancer drugs in 2025, at 25.4 billion rubles, according to Cursor analytics as reported by GxP News. [4] I could not verify the Cursor figure against a primary procurement database. This article treats it as a secondary figure.
The figure still shows the commercial logic. A state buyer that spends 25.4 billion rubles on one molecule has strong reasons to favor domestic, lower-priced versions. BIOCAD says its pembrolizumab biosimilar could treat about 25% more patients without raising the healthcare budget burden. [1] That is a company claim, and it lacks a stated price.
How Did Russia Register a Pembrolizumab Biosimilar in 148 Days?
Russia used an accelerated procedure for drugs on a shortage-risk list. Government Decree 593 of April 5, 2022 created the list. An interdepartmental commission drew it up after finding a risk of shortages from economic sanctions. Pembrolizumab was on it. [1]
What Is Russia’s Accelerated Registration List?
The list is a policy tool, not a patent tool. It shortens the path to market for products the state wants available. Nothing in the sources reviewed says Russia links registration to patent status. The Pharmvestnik report on BIOCAD’s filing mentions that patent protection for Keytruda expires in 2028, and it still describes Pembroria as the first generic of the original drug. [3] This suggests that registration went ahead without waiting for the patent date. I did not find a Russian court ruling on whether Pembroria infringes any Keytruda patent.
How Does BIOCAD’s Evidence Package Compare With Formycon’s FDA Path?
The two packages differ in design. They are not strictly comparable, because they answer to different regulators.
| Feature | BIOCAD BCD-201 (Pembroria) | Formycon/Zydus FYB206 |
|---|---|---|
| Regulator and status | Russian registration, Dec. 2, 2022 [1] | FDA BLA accepted, announced Oct. 13, 2026 [15] |
| Reported equivalence evidence | BIOCAD says melanoma and NSCLC trials showed equivalent PK, PD, safety and immunogenicity [1] | Dahlia trial (NCT06551064): about 96 patients, primary PK equivalence met, reported Feb. 2026 [15] |
| Comparative efficacy trial | BCD-201-2 compares efficacy and safety with Keytruda in first-line melanoma, in Russia and Belarus [16] | FDA agreed in Feb. 2025 that a comparative phase 3 efficacy trial is not required [15] |
| Trial completion at registration | July 2022 registry data listed three BIOCAD pembrolizumab trials due to finish in 2023, 2026 and 2027 [3] | Not applicable; filing made in Q3 2026 [15] |
One calculated observation follows. When Pembroria was registered in December 2022, two of the three BIOCAD trials in the registry (due 2026 and 2027) had not reached their listed end dates. This is based on a July 2022 report. Later records may have changed the dates, and Tuoi Tre reports that the latest phase 3 study finished in January 2024. [18]
Which Pembrolizumab Analogues Are Registered in Russia Today?
GxP News reported on May 29, 2026 that the Ministry of Health registered Pembronext, which it calls the third analogue of Keytruda. [4] The two earlier ones are BIOCAD’s Pembroria and R-Pharm’s Arfleyda. [4]
| Product | Developer or holder | Manufacturing | Certificate validity | Source |
|---|---|---|---|---|
| Pembroria | BIOCAD | Russia, full cycle including active substance synthesis | Not stated in sources | [1] |
| Arfleyda | R-Pharm | Not stated in sources | Not stated in sources | [4] |
| Pembronext (25 mg/ml concentrate) | MIT (Medical Innovations and Technologies), mainly a distributor; its first registered product | CinnaGen, Iran, all stages | To end of 2027 | [4] |
What Happens to Price When Three Analogues Compete?
The sources give no Russian price data for any of the three. This article does not forecast price. The structural fact is that a state buyer now has three registered alternatives to one reference product, and one of them is made outside Russia. That fact weakens any claim that import substitution alone explains BIOCAD’s position.
Pertuzumab: BIOCAD’s Live Patent Test Against Roche
What Did Rospatent Decide on Russian Patent 2426554?
Rospatent’s collegium rejected BIOCAD’s objection to patent 2426554, reported on February 19, 2026. [5] The patent is titled “Antibody Compositions” and covers a stable pharmaceutical form of pertuzumab. [5] Its key formula claims run to March 22, 2028. [5]
BIOCAD filed the objection in October 2024 (No. 2024V03423). It argued that a histidine-acetate buffer with sucrose and polysorbate-20 lacked an inventive step. [5] Genentech answered that its formulation uses a histidine-acetate buffer at pH 5.5 to 6.5, reduces aggregation under agitation and freeze-thaw cycles compared with histidine-chloride buffers, and avoids oxidation in stainless steel containers. [5] Rospatent found no public prior art, before the priority date, on histidine-acetate buffer for pertuzumab. [5]
The proceeding ran about 16 months from objection to the February 2026 report (calculated). The source gives no exact decision date.
Is Genentech Suing BIOCAD Over Pertuvia in Russia?
Yes. Genentech began patent infringement proceedings in the Moscow Arbitration Court over BIOCAD’s pertuzumab biosimilar Pertuvia, reported on March 10, 2026. [6] BIOCAD received approval for Pertuvia in May 2025. [6] The report does not name the asserted patents and does not state the relief sought. [6]
The Pharma Letter says the suit puts at risk the market BIOCAD expanded in 2025. [20] The Rospatent ruling was reported 19 days before the suit report (calculated). A link between the two is plausible. The sources do not confirm it.
How Does the Biocon Settlement Show the Global Pertuzumab Timeline?
On October 14, 2026, Biocon announced a global settlement with Genentech for its pertuzumab biosimilar Pebrilzo (Bmab 1500). The terms set licensed launch dates of Q1 2027 in the EU and UK, Q3 2028 in the US, and 2026 to 2028 in other countries. [21] The settlement closed a July 2026 BPCIA case on 28 US patents and a February 2026 ITC complaint. [21] The CHMP gave a positive opinion in September 2026. [21]
| Event | BIOCAD (Pertuvia) | Biocon (Pebrilzo) |
|---|---|---|
| Regulatory status | Approved in Russia, May 2025 [6] | CHMP positive opinion, Sept. 2026; US aBLA submitted [21] |
| Patent dispute | Rospatent upheld patent 2426554 (to Mar. 22, 2028); Moscow Arbitration Court suit [5][6] | ITC complaint (Feb. 2026) and BPCIA suit on 28 US patents (July 2026), settled Oct. 14, 2026 [21] |
| Earliest licensed or expected entry | On the market per approval; exposure to the Genentech suit | EU/UK Q1 2027; US Q3 2028; other markets 2026 to 2028 [21] |
Two calculations follow, both on approval dates, not like-for-like launch dates. Pertuvia’s Russian approval came about 20 to 22 months before Biocon’s licensed EU and UK entry, and about 38 to 40 months before its licensed US entry. The Russian patent’s March 2028 date sits about 2.8 years after Pertuvia’s approval.
What Happens If Genentech Wins in the Moscow Arbitration Court?
The sources do not say what remedy Genentech seeks. Under one assumption, an injunction or damages remedy would cover the period to March 22, 2028, about 2.8 years from approval. Under a second assumption, the court finds no infringement, and Pertuvia stays on the market. I have no evidence for either outcome. This is scenario framing, not a forecast.
BIOCAD vs. Roche: The Earlier Fights Over Rituximab, Trastuzumab and Bevacizumab
Did BIOCAD Invalidate a Genentech Rituximab Patent in Russia?
Yes, in part of the record. The Pharma Letter reported on October 25, 2017 that the Chamber for Patent Disputes of the Russian patent office announced the operative part of a decision declaring Genentech’s rituximab patent “completely invalid.” [22] The case concerned use of the drug in rheumatoid arthritis. [22] In the same week BIOCAD announced plans to enter European markets. [22] The article gives no patent number.
What Happened When Roche Sued Over BIOCAD Biosimilars in Sri Lanka?
Roche sued a local distributor of BIOCAD products in the Court of Appeals of Sri Lanka in late March 2016. The suit targeted trastuzumab and bevacizumab. [23] Roche alleged manufacturing process violations during approval and a lack of proper clinical trials. [23] The court dismissed the suit in June 2016 and lifted an interim stay order on distribution and sale. [23] BIOCAD says the stay blocked trastuzumab in Sri Lankan hospitals and that patients waited several months. [23] The article rests on a BIOCAD statement, and it does not give Roche’s response or the full court reasoning.
Why Did BIOCAD’s US Antitrust Case Against Roche Fail?
The Second Circuit affirmed dismissal on November 5, 2019 in BIOCAD JSC v. F. Hoffmann-La Roche Ltd., No. 17-3486. [24] BIOCAD alleged price fixing, illegal tying and price discrimination in Russia, aimed at blocking its planned US entry with biosimilars of bevacizumab, trastuzumab and rituximab. [24] The court held that the Foreign Trade Antitrust Improvements Act barred the Sherman Act claims. [24]
What Did the Court Hold on Import Commerce?
The court wrote that “the import exclusion applies to conduct by a defendant that has a direct or immediate effect on import commerce.” [24] Conduct merely intended to affect future imports did not qualify. [24] BIOCAD had never sold in the US market. [24] The court did not reach antitrust standing, and it declined to consider the domestic-effects exception because BIOCAD had waived it. [24]
Chief Judge Katzmann concurred in the result. He would not require a showing of probable FDA approval for a potential entrant to plead antitrust injury. [24] The US record is the only place where a court reviewed BIOCAD’s own claims against Roche on the merits of jurisdiction. It shows one limit of the strategy: US courts did not accept Russian conduct as a US antitrust harm.
Daratumumab: What Daratumia’s Registration Does and Does Not Show
GxP News reported on August 25, 2025 that the Russian Ministry of Health registered Daratumia, BIOCAD’s daratumumab biosimilar for multiple myeloma. [25] The article describes it as the country’s first daratumumab biosimilar. It does not claim a world first. [25] BIOCAD says it developed and produced the drug in Russia, including synthesis of the active substance. [25]
Daratumumab sees most use in Russia as a later-line therapy, largely because of price. BIOCAD says a domestic version allows earlier access. [25] The source gives no patent information for the reference product in Russia, and I found none elsewhere. This article therefore makes no patent claim about Daratumia. Teams that track the molecule should look for Russian patent records before they assume freedom to operate or a patent gap.
Prolgolimab: BIOCAD’s Own PD-1 Antibody
What Does the FLAT Trial Show for Prolgolimab?
Prolgolimab (Forteca) is a BIOCAD-developed PD-1 antibody. It was first approved in Russia in 2020 for metastatic or unresectable melanoma. [26] The 250 mg every-3-weeks dose is approved in Russia for melanoma and NSCLC, and first-line NSCLC use with platinum chemotherapy was approved at the end of 2023 based on the DOMAJOR study. [26]
The FLAT trial (NCT05783882) was a single-arm, open-label phase III study in first-line melanoma. It enrolled 114 patients on 250 mg every 3 weeks and compared them with a historical control of 61 patients from the MIRACULUM study at 1 mg/kg every 2 weeks. [26] The objective response rate was 33.3% (38 of 114; 95% CI 24.8 to 42.8) against 32.8% (20 of 61). [26] Grade 3 or higher adverse events occurred in 18.4% against 23.0%. [26] The authors list the historical control as a limitation. [26]
Is Prolgolimab a Substitute for Pembrolizumab?
The sources contain no head-to-head trial of prolgolimab against pembrolizumab. This article does not claim equivalence. BIOCAD pursues both: its own PD-1 antibody and a pembrolizumab biosimilar. A US or EU competitor should read that as a hedge, not as proof that either product competes on efficacy. BIOCAD also runs international prolgolimab trials in China through a joint venture with a possible total investment above $35 million. [10]
Russia’s Patent Rules: Compulsory Licences and Zero Compensation
What Does Russian Government Decree 299 Do to Foreign Patent Holders?
Decree 299 of March 6, 2022 amends the compensation rule in Article 1360 of the Russian Civil Code. When the patent holder is a citizen of, is registered in, or has its main place of business in one of 48 designated countries, compensation for unauthorized use of an invention, utility model or industrial design is 0%. [7] The countries named include the US, Canada, Australia, Switzerland, Norway, Iceland, the UK, Japan, South Korea and all 27 EU member states. [7] The source does not list all 48.
The decree covers inventions, utility models and industrial designs. [7] It does not by itself license anything. It sets the price when a license or use happens.
Case Study: How Did Russia License Novo Nordisk’s Semaglutide Patents?
The semaglutide record is the clearest Russian example of Article 1360 in action. It is not an oncology case. It still shows how courts handle the legal test.
GxP News reported on August 15, 2025 that the Appeals Board of the Supreme Court of Russia rejected Novo Nordisk’s complaint against government orders that allowed PSK Pharma and Promomed Rus to make semaglutide through the end of 2025. [27] The legal basis was Article 1360, which permits use of a patent without the holder’s consent in an emergency. [27] Six Novo Nordisk patents were on the list. [27] Novo argued that no emergency existed, that it received no notice, and that it received no compensation. [27] The court found that halting Ozempic and Rybelsus supply from January 1, 2024 threatened patient health, and it noted that semaglutide is on Russia’s list of vital and essential drugs. [27]
On May 25, 2026, GxP News reported that the Moscow Arbitration Court granted Biokhimik, part of the Promomed Group, a simple (non-exclusive) licence on two semaglutide production patents. The licence runs for the full patent term, including any extension, and the royalty is 1.75% of actual drug sales revenue. [8] The ruling had not taken effect and could be appealed. [8] The court rejected Novo Nordisk’s argument that rising global demand justified prioritizing other countries, and it noted Novo gave no evidence of plans to resume deliveries. [8] Eleven Ozempic analogues were registered in Russia. [8] Pharmacy sales of semaglutide and tirzepatide obesity drugs reached 17 billion rubles in Q1 2026, up from 5.2 billion rubles in Q1 2025, per RNC Pharma. [8] That is a 3.3-fold increase (calculated).
The two GxP reports date the government licensing orders differently. One says December 2023, and the other says November and December 2024. This article does not resolve that difference.
Zero Percent Versus 1.75%: What Changes for Patent Valuation?
Decree 299 sets 0% for holders from designated countries. [7] The Biokhimik ruling sets 1.75%. [8] Illustration: on 1 billion rubles of licensee sales, 1.75% is 17.5 million rubles, and 0% is zero. This is arithmetic, not a forecast. The gap suggests that courts may not apply the decree’s zero rate mechanically. The sources do not explain how the court reached 1.75%.
Could Russia License a Cancer Biologic the Same Way?
No source I reviewed reports a compulsory licence for an oncology biologic. The semaglutide orders rested on a supply halt, and the Moscow court expressly noted Novo’s halted deliveries. [8][27] GxP News reports that MSD sells Keytruda in Russia. [4] On those facts, a supply-halt argument would not fit pembrolizumab in the same way. This is analysis from documented facts. It is not a legal opinion. The pertuzumab suit shows the other path: Genentech enforces a patent in the ordinary court system, and BIOCAD defends. [6]
An Original Framework: Four Types of BIOCAD IP Exposure
The cases above fall into four groups. This framework is original to this article. It is not an established industry classification. It sorts the documented record by the mechanism through which a BIOCAD product meets a Western patent.
| Type | Mechanism | Documented example | Outcome in the record | Source |
|---|---|---|---|---|
| Type 1: Pre-expiry domestic registration | Register a biosimilar in Russia while the reference patent runs elsewhere | Pembroria, registered Dec. 2, 2022; US patent 2028 | Registered; three analogues now in Russia | [1][2][4] |
| Type 2: Formulation-patent contest | Challenge a formulation patent at Rospatent, then face infringement suit | Patent 2426554 (pertuzumab) | Challenge rejected, Feb. 2026; Moscow suit reported Mar. 2026 | [5][6] |
| Type 3: Patent invalidation | Seek invalidity of a use or composition claim | Genentech rituximab patent (rheumatoid arthritis use) | Declared “completely invalid,” Oct. 2017 report | [22] |
| Type 4: Export registration and court tests | Register abroad; defend against originator suits; test antitrust theories | Sri Lanka 2016; Vietnam 2025; Second Circuit 2019 | Sri Lanka suit dismissed; Vietnam approval; US antitrust claims dismissed | [23][17][24] |
The table records seven events. BIOCAD advanced in four (the Pembroria registration, the rituximab invalidation, the Sri Lanka dismissal and the Vietnam approval). It lost two (the Rospatent pertuzumab ruling and the Second Circuit ruling). The Moscow suit is unresolved in the sources. This tally is mine. With seven events it shows a pattern, not a rate.
What This Means for Brand Manufacturers, Biosimilar Developers and Investors
What Does BIOCAD Mean for Merck’s Keytruda Loss-of-Exclusivity Planning?
For the US, the Merck calendar does not change. The 10-K gives 2028, with two further patents to 2029 and a stated expectation of litigation. [2] DrugPatentWatch lists later US patents with expiry dates from 2035 to 2040, and it labels several of them low certainty. [14] Formycon’s FDA filing is the nearer test of that calendar, not BIOCAD. [15]
What About Keytruda Qlex and the 2031 and 2043 Dates?
Merck lists Keytruda Qlex expiry as 2043 in the US and 2031 in the EU, and it notes a pending application that would expire in 2040 if granted. [2] A biosimilar of intravenous pembrolizumab does not automatically replace the subcutaneous product. This article found no source that tests that question, so it makes no claim on substitution.
What Does BIOCAD Mean for Roche and Genentech?
Roche now defends pertuzumab on three fronts that the sources document: a Russian suit against BIOCAD, a settled Biocon dispute with licensed dates in 2027 and 2028, and a settled Henlius/Organon dispute with no announced launch dates. [6][21] The Russian formulation patent runs to March 22, 2028. [5] The Biocon US licensed date is Q3 2028. [21] Roche’s Russian and US positions end within months of each other.
What Does BIOCAD Mean for Western Biosimilar Developers?
BIOCAD and Western developers may meet in the same third-country tenders. BIOCAD holds a three-year Vietnamese authorization for Pembroria. [17] Formycon’s FYB206 has a licensing deal for the Middle East and North Africa. [19] These are different regions, so I do not claim direct overlap. The point is narrower: BIOCAD’s evidence package, which includes a comparative melanoma efficacy trial design, is a different package from the PK-only path that the FDA accepted for FYB206. [15][16] Buyers in third markets can compare them.
What Does BIOCAD Mean for Generic Entry and LOE Forecasts?
Forecast models that use one global LOE date for pembrolizumab are wrong for Russia. Russia has had a registered analogue since December 2022. [1] A better model carries separate dates by jurisdiction and separates three events: registration, patent expiry, and licensed launch. The Biocon pertuzumab settlement shows why. One product has licensed dates in Q1 2027 (EU and UK), Q3 2028 (US) and a 2026 to 2028 range elsewhere. [21]
Scenario Analysis: Three Assumption-Based Paths Through 2028
These scenarios are not forecasts. Each states an assumption and a documented signal that would support it.
| Scenario | Assumption | Signal that would support it |
|---|---|---|
| A: Export expansion | Vietnam-style approvals continue in emerging markets | More authorizations like Vietnam’s Nov. 2025 approval, or further free-supply programs like Cuba’s [17] |
| B: Roche wins in Moscow | The Moscow Arbitration Court finds infringement of a pertuzumab patent | A published ruling naming patents and remedy; the sources name neither [6] |
| C: Western filing | BIOCAD files for FDA or EMA review of a biosimilar | A public BLA or MAA announcement; I found none in the sources reviewed |
Scenario C has no documented support today. The Second Circuit record shows BIOCAD planned US entry once Roche’s exclusivity ended, but it also states that BIOCAD had never sold in the US. [24] That record dates from 2019.
How to Monitor BIOCAD’s Patent and Regulatory Events
Which Records Should a Competitive Intelligence Team Check?
Four record types cover the events in this article. First, the Russian State Register of Medicines, where the filing and registration of Pembroria appeared. [3] Second, Rospatent decisions, such as the pertuzumab ruling. [5] Third, the Moscow Arbitration Court docket for the Genentech suit. [6] Fourth, trial registries. BIOCAD’s own trial site lists BCD-201-2 with Russian and Belarusian authorizations (Russia No. 433 of July 5, 2022; Belarus No. 50/1305/2022 of September 28, 2022), and ClinicalTrials.gov carries NCT05739006 and NCT05986331 for BCD-201 against Keytruda. [16][28][29]
Where Does DrugPatentWatch Fit in This Workflow?
DrugPatentWatch supplies the US reference points. Its pembrolizumab page lists BLA 125514, FDA approval on September 4, 2014, a 12-year biologic exclusivity date of September 2026, a central patent (8,354,509) with a May 2028 expiry, and US patent entries with expiry dates from 2035 to 2040. [14] The page flags some entries as low certainty and states that it found no brand-side litigation. [14] Use it with the Russian records above. It does not replace Merck’s SEC filing or a court docket. For a patent date that drives a decision, check the filing and the docket.
Key Takeaways
- BIOCAD’s Pembroria was registered in Russia on December 2, 2022, about 6.1 years before the 2028 US patent expiry in Merck’s 10-K. [1][2]
- Three pembrolizumab analogues are registered in Russia: Pembroria, Arfleyda and Pembronext. [4]
- The FDA’s 12-year exclusivity for Keytruda ended on September 4, 2026 (calculated). Patents now control US entry. [9][14]
- The first publicly announced FDA acceptance of a pembrolizumab biosimilar filing is FYB206’s, announced October 13, 2026, with a possible decision in Q3 2027. [15]
- Rospatent rejected BIOCAD’s challenge to Genentech’s pertuzumab formulation patent 2426554, which runs to March 22, 2028. Genentech then sued in Moscow. [5][6]
- Russia’s Decree 299 sets 0% compensation for patent holders from 48 designated countries, while a May 2026 semaglutide ruling set 1.75%. [7][8]
- No source reviewed reports a BIOCAD filing with the FDA or EMA.
FAQ: BIOCAD, Keytruda Biosimilars and Russian Patent Rules
Does the 2028 Keytruda Date Mean a US Biosimilar Launches in 2028?
Not necessarily. Merck gives 2028 as the US expiry year. It also says two further patents expire in 2029 and that it expects litigation over them. [2] DrugPatentWatch lists other US patents with dates from 2035 to 2040. [14] A launch date depends on FDA approval, patent outcomes and any settlement.
Can the FDA Approve a Pembrolizumab Biosimilar Now?
The 12-year statutory bar ended on September 4, 2026, calculated from the September 4, 2014 licensure date. [9][14] The FDA has accepted one filing, for FYB206, and a decision could come in Q3 2027. [15] No approval is reported in the sources reviewed.
What Did the FDA Agree to for Formycon’s Pembrolizumab Biosimilar?
In February 2025, Formycon reached an FDA agreement that a comparative phase 3 efficacy trial would not be required. The company relies on analytical characterization and PK data. [15]
Does Russia Link Drug Registration to Patent Status?
No source I reviewed says so. Pharmvestnik described Pembroria as the first generic of Keytruda while noting that Keytruda’s patent protection expires in 2028. [3] I found no Russian court ruling that tests Pembroria against a Keytruda patent.
What Does Russian Patent 2426554 Cover?
It covers a stable pharmaceutical form of pertuzumab, titled “Antibody Compositions.” The key formula claims run to March 22, 2028. [5]
How Does Decree 299 Affect Western Patent Holders?
It sets 0% compensation for unauthorized use of an invention, utility model or industrial design when the holder comes from one of 48 designated countries. [7] It does not itself grant a licence.
What Royalty Did the Russian Court Set for Semaglutide?
The Moscow Arbitration Court set 1.75% of actual sales revenue for Biokhimik on a non-exclusive licence over two Novo Nordisk patents. The ruling was reported on May 25, 2026 and could be appealed. [8]
Where Does BIOCAD Sell Outside Russia?
Its three main biosimilars ship to more than 20 countries. [10] The record shows a three-year authorization in Vietnam for Pembroria, free supply of anticancer drugs to Cuba since 2023 (BIOCAD’s statement), and a 2016 Sri Lankan court dispute over trastuzumab and bevacizumab. [17][23]
How Many Other Companies Are Developing a Pembrolizumab Biosimilar?
The sources name at least ten other developers or partnerships: Samsung Bioepis, Amgen, mAbxience, Sandoz, Celltrion, Bio-Thera, BioNTech, Alvotech with Dr. Reddy’s, Formycon with Zydus and MS Pharma, and Biocon. [17][19] The count is mine, and it is a floor.
What BIOCAD Revenue Figures Are Public?
The most recent figure in the sources reviewed is for 2018: 21.7 billion rubles in net revenue, up 39.5%, with exports at 9.44% of revenue. [11] BIOCAD is privately held, and I found no later audited figure.
References
- GxP News. (2022, December 6). Минздрав зарегистрировал биоаналог пембролизумаба [Ministry of Health registered pembrolizumab biosimilar]. https://gxpnews.net/2022/12/minzdrav-zaregistriroval-bioanalog-pembrolizumaba/
- Merck & Co., Inc. (2026). Form 10-K for the fiscal year ended December 31, 2025. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm
- Doguzova, V. (2022, July 7). «Биокад» подала документы на регистрацию аналога «Китруды» [BIOCAD filed documents to register a Keytruda analogue]. Pharmvestnik. https://pharmvestnik.ru/content/news/Biokad-podal-dokumenty-na-registraciu-analoga-Kitrudy.html
- GxP News. (2026, May 29). Минздрав зарегистрировал третий аналог «Китруды» [Ministry of Health registered third analogue of Keytruda]. https://gxpnews.net/2026/05/minzdrav-zaregistriroval-tretij-analog-kitrudy/
- PharmProm.Net. (2026, February 19). BIOCAD loses patent dispute: Rospatent upholds Genentech’s protection for pertuzumab. https://pharmprom.net/biocad-loses-patent-dispute-rospatent-upholds-genentechs-protection-for-pertuzumab/
- Pearce IP. (2026, March 10). Roche sues Biocad in Russia for patent infringement regarding biosimilar pertuzumab. https://www.pearceip.law/2026/03/10/roche-sues-biocad-in-russia-for-patent-infringement-regarding-biosimilar-pertuzumab/
- William Fry. (2022). Russia issues decree providing for 0% compensation for the unauthorised use of certain IP rights emanating from unfriendly countries. https://www.williamfry.com/knowledge/russia-issues-decree-providing-for-0-compensation-for-the-unauthorised-use-of-certain-ip-rights-emanating-from-unfriendly-countries/
- GxP News. (2026, May 25). Russian court grants Biokhimik compulsory licence for Novo Nordisk’s semaglutide patents. https://gxpnews.net/en/2026/05/russian-court-grants-biokhimik-compulsory-licence-for-novo-nordisks-semaglutide-patents/
- Biologics Price Competition and Innovation Act, 42 U.S.C. § 262(k)(7). https://www.law.cornell.edu/uscode/text/42/262
- European Pharmaceutical Review. (n.d.). Evolving into an international biotech market driver. https://www.europeanpharmaceuticalreview.com/?p=167512
- Pharmvestnik. (2019, February 14). Выручка BIOCAD за год выросла почти на 40% [BIOCAD revenue grew almost 40% in a year]. https://pharmvestnik.ru/content/news/Vyruchka-BIOCAD-za-god-vyrosla-pochti-na-40.html
- Office of Foreign Assets Control. (2024, October 30). FAQ 1198. U.S. Department of the Treasury. https://ofac.treasury.gov/faqs/1198
- TradeCompliance.io. (n.d.). Effects of sanctions on Russia’s pharmaceutical landscape. https://www.tradecompliance.io/effects-sanctions-russias-pharmaceutical-landscape
- DrugPatentWatch. (2026, July 6). Pembrolizumab (Keytruda) biologics page. https://www.drugpatentwatch.com/p/biologics/ingredient/Pembrolizumab
- Targeted Oncology. (2026, October 15). FDA accepts BLA for pembrolizumab biosimilar FYB206. https://www.targetedonc.com/view/fda-accepts-bla-pembrolizumab-biosimilar-fyb206
- BIOCAD. (n.d.). BCD-201-2 clinical study page. https://ct.biocad.ru/en/nozology/bcd-201-2
- Pearce IP. (2025, November 11). Russian pembrolizumab biosimilar approved in Vietnam. https://www.pearceip.law/2025/11/11/russian-pembrolizumab-biosimilar-approved-in-vietnam/
- Tuoi Tre News. (2025, November 14). Russia’s cancer drug approved in Vietnam or still under trial. https://news.tuoitre.vn/russias-cancer-drug-approved-in-vietnam-or-still-under-trial-103251113170915616.htm
- Pearce IP. (2026, January 6). Biocon to add pembrolizumab, nivolumab, trastuzumab SC biosimilars to its portfolio. https://www.pearceip.law/2026/01/06/biocon-to-add-pembrolizumab-nivolumab-trastuzumab-sc-biosimilars-to-its-portfolio/
- The Pharma Letter. (2026, March 10). Russia’s Biocad risks losing market for cancer drug pertuzumab due to Roche dispute. https://www.thepharmaletter.com/biosimilars-news/russia-s-biocad-risks-losing–market-for-cancer-drug-pertuzumab-due-to-roche-dispute
- Pearce IP. (2026, October 14). Biocon enters global settlement with Genentech for biosimilar pertuzumab. https://www.pearceip.law/2026/10/14/biocon-enters-global-settlement-with-genentech-for-biosimilar-pertuzumab/
- The Pharma Letter. (2017, October 25). Through Russian courts and into Europe, BIOCAD’s bandwagon rolls on. https://www.thepharmaletter.com/article/through-russian-courts-and-into-europe-biocad-s-bandwagon-rolls-on
- Daily FT. (2016, July 7). Court dismisses lawsuit to ban distribution of anti-cancer drugs produced by BIOCAD. https://www.ft.lk/Healthcare/court-dismisses-lawsuit-to-ban-distribution-of-anti-cancer-drugs-produced-by-biocad/45-553127
- BIOCAD JSC v. F. Hoffmann-La Roche Ltd., No. 17-3486 (2d Cir. Nov. 5, 2019). https://caselaw.findlaw.com/court/us-2nd-circuit/2029500.html
- GxP News. (2025, August 25). Russia has registered the first biosimilar of daratumumab for multiple myeloma. https://gxpnews.net/en/2025/08/russia-has-registered-the-first-biosimilar-of-daratumumab-for-multiple-myeloma
- Demidov, L., et al. (2024). A phase III study to assess the safety and efficacy of prolgolimab 250 mg fixed dose every 3 weeks versus 1 mg/kg every 2 weeks in metastatic melanoma (FLAT). Frontiers in Oncology, 14, 1385685. https://doi.org/10.3389/fonc.2024.1385685
- GxP News. (2025, August 15). The Supreme Court of Russia allowed the production of Ozempic versions without the consent of the patent owner. https://gxpnews.net/en/2025/08/the-supreme-court-of-russia-allowed-the-production-of-ozempic-versions-without-the-consent-of-the-patent-owner/
- ClinicalTrials.gov. (n.d.). Clinical trial to evaluate the PK and safety of BCD-201 and Keytruda in patients with advanced malignancies (NCT05739006). https://clinicaltrials.gov/study/NCT05739006
- ClinicalTrials.gov. (n.d.). Clinical study of the efficacy and safety of BCD-201 and Keytruda in subjects with advanced melanoma (NCT05986331). https://clinicaltrials.gov/study/NCT05986331


























